secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001193125-23-203902
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Auditor Mayer Hoffman McCann declines reappointment; FY2022 tax-provision controls deemed ineffective
--------------------------------------------------------------------------------

- MHM will not stand for re-appointment for FY2024; will cease by new auditor appointment, filing of 2023 10-K, or April 1, 2024.
- No disagreements between company and MHM on accounting principles or audit scope for FY2021 and FY2022.
- Reportable event: management concluded ineffective controls over completeness and accuracy of annual tax provision in FY2022 10-K.
- Audit committee will initiate process to select a new independent registered public accounting firm.
- MHM’s audit reports for FY2021 and FY2022 were unqualified, with no adverse opinion or disclaimer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523203902/0001193125-23-203902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523203902/d416994d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-203902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer